Wells Fargo & Company Veracyte, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Veracyte, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 96,375 shares of VCYT stock, worth $2.22 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
96,375
Previous 82,260
17.16%
Holding current value
$2.22 Million
Previous $2.26 Million
5.61%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding VCYT
# of Institutions
252Shares Held
81.2MCall Options Held
43KPut Options Held
82K-
Vanguard Group Inc Valley Forge, PA7.38MShares$170 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA7.37MShares$170 Million0.03% of portfolio
-
Black Rock Inc. New York, NY7.21MShares$166 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.81MShares$157 Million1.34% of portfolio
-
State Street Corp Boston, MA4.33MShares$99.7 Million0.0% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $1.65B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...